Belatacept

Nature Reviews Drug Discovery

Volumn 10, Issue 9, 2011, Pages 655-656

  Vincenti, Flavio ^a   Dritselis, Argyris ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ASKP 120; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ASKP 120; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NULOJIX; STEROID; TACROLIMUS; TOFACITINIB; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; ATROPHY; CELL PROLIFERATION; CELLULAR IMMUNITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE DRUG DOSE; NEPHROTOXICITY; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; PROTEIN DOMAIN; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; GRAFT REJECTION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; T-LYMPHOCYTES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80052208626     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3536     Document Type: Article

References (8)

1. Webber, A., Hirose, R. & Vincenti, F. Novel strategies in immunosuppression: issues in perspective. Transplantation 91, 1057-1064 (2011).
2. Lamb, K. E., Lodhi, S. & Meier-Kriesche, H.-U. Long-term renal allograft survival in the United States: a critical reappraisal. Am. J. Transplant. 11, 450-462 (2011).
3. Linsley, P. S. et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257, 792-795 (1992).
4. Larsen, C. P. et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5, 443-453 (2005). (Pubitemid 40313335)
5. US Food and Drug Administration. FDA labeling information-Nulojix. FDA website [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 125288s0000lbl.pdf (2011).
6. Vincenti, F. et al. A Phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10, 535-546 (2010).
7. Durrbach, A. et al. A Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am. J. Transplant. 10, 547-557 (2010).
8. Gaston, R. S. et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 290, 68-74 (2010).